The treatment for hemolytic anemia depends entirely on why the red cells are being destroyed. Autoimmune forms are usually treated with corticosteroids and, increasingly, with targeted antibodies such as rituximab; complement-driven diseases now have dedicated complement inhibitors; and several inherited forms have new disease-modifying drugs or gene therapies. Supportive care, including folic acid and transfusion when needed, underpins every approach.
In this article I walk through the established treatments and the newer, more innovative options that have changed practice in recent years. For background on the specialty itself, see our clinical perspective on haematology.
What Is Hemolytic Anemia?
Hemolytic anemia occurs when erythrocytes are destroyed faster than the bone marrow can replace them. A healthy red cell survives about 120 days; in hemolysis that lifespan can shrink to weeks or days.
Causes fall into two broad groups. Intrinsic causes are defects in the red cell itself, usually inherited, such as sickle cell disease, thalassemia, hereditary spherocytosis, G6PD deficiency, and pyruvate kinase deficiency. Extrinsic causes act on normal cells from outside, including autoimmune antibodies, infections, certain drugs, mechanical damage from heart valves, and paroxysmal nocturnal hemoglobinuria (PNH), an acquired stem cell disorder.
Typical symptoms are fatigue, pallor, jaundice, dark urine, and an enlarged spleen. Laboratory hallmarks include a raised reticulocyte count, high LDH and unconjugated bilirubin, and low haptoglobin. The direct antiglobulin (Coombs) test separates immune from non-immune causes and is often the pivot on which treatment decisions turn.
Foundations of Treatment
Whatever the cause, a few principles apply to almost every patient:
- Remove the trigger where possible: stop an implicated drug, treat an infection, or avoid oxidant foods and medicines in G6PD deficiency.
- Folic acid supplementation, because a marrow working overtime to make new red blood cells uses folate rapidly.
- Transfusion for severe or symptomatic anemia. In autoimmune hemolysis, crossmatching can be difficult, but transfusion should not be withheld in a life-threatening situation.
- Thromboprophylaxis consideration, since active hemolysis, especially in PNH and autoimmune disease, raises the risk of blood clots.
Treating Autoimmune Hemolytic Anemia
Autoimmune hemolytic anemia (AIHA) is divided by the temperature at which the antibody binds best, and the two types are treated differently.
Warm AIHA
Warm AIHA is usually IgG-mediated, with red cells cleared mainly in the spleen. First-line therapy is corticosteroids, typically prednisone at around 1 mg/kg per day, tapered slowly once hemoglobin recovers. Rituximab, an anti-CD20 antibody that depletes antibody-producing B cells, is the standard second-line option and is increasingly added earlier to reduce relapse and steroid exposure. Splenectomy remains effective for some patients who do not respond, and other immunosuppressants such as azathioprine or mycophenolate are used as steroid-sparing agents.
Cold agglutinin disease
Cold agglutinin disease is usually IgM-mediated and driven by the classical complement pathway. Steroids work poorly here. Keeping warm, particularly the hands and feet, and warming transfusions are practical basics. Rituximab-based therapy can induce remission, and sutimlimab, an antibody that blocks complement protein C1s, is an approved targeted option that directly halts the hemolysis.
Look for an underlying cause
A substantial proportion of autoimmune cases are secondary, linked to conditions such as lupus, chronic lymphocytic leukemia, lymphoma, or certain infections. Screening for these is part of the initial workup, because treating the underlying disease often controls the hemolysis more effectively than immunosuppression alone.
Innovative Approaches: Complement and Enzyme Targets
The biggest recent shift in the treatment for hemolytic anemia has come from drugs aimed at the exact molecular step that destroys the cell.
| Condition | Innovative therapy | How it works |
|---|---|---|
| PNH | Eculizumab, ravulizumab | Block complement C5, preventing cell lysis in the blood vessels |
| PNH | Pegcetacoplan | Blocks complement C3, reducing destruction in the vessels and the spleen |
| PNH | Iptacopan (oral) | Inhibits factor B of the alternative complement pathway |
| Cold agglutinin disease | Sutimlimab | Blocks C1s of the classical complement pathway |
| Pyruvate kinase deficiency | Mitapivat (oral) | Activates the defective red cell enzyme to restore energy production |
| Beta thalassemia | Luspatercept | Improves late-stage red cell maturation, lowering transfusion needs |
Complement inhibitors carry one important caution: they raise the risk of serious infection with encapsulated bacteria, especially meningococcus. Vaccination before starting treatment, and sometimes preventive antibiotics, are required.
Gene therapy for inherited hemolytic anemias
For inherited conditions, gene-based treatments now offer the possibility of long-term correction rather than lifelong management.
- Sickle cell disease: gene therapies include a CRISPR-based therapy that reactivates fetal hemoglobin and a lentiviral approach that adds a modified hemoglobin gene. These sit alongside hydroxyurea, crizanlizumab, and allogeneic stem cell transplant. Our article on sickle cell anemia treatment options covers these in depth.
- Transfusion-dependent beta thalassemia: gene addition and gene editing therapies can free many patients from regular transfusions.
These therapies use the patient’s own stem cells, which are collected, modified, and returned after conditioning chemotherapy. They are intensive, expensive, and available only at specialist centers, so careful patient selection remains essential.
Other Established Options
Splenectomy is still valuable in selected cases. In hereditary spherocytosis, removing the spleen, sometimes partially in young children, can greatly reduce hemolysis. Vaccination against encapsulated organisms before surgery is mandatory. In G6PD deficiency, treatment is almost entirely preventive: avoiding fava beans and oxidant drugs, and treating infections promptly.
Microangiopathic hemolytic anemia, in which red cells are sheared in small blood vessels, needs a different and urgent approach. In thrombotic thrombocytopenic purpura (TTP), plasma exchange and immunosuppression are the backbone of treatment, and caplacizumab, an antibody that blocks von Willebrand factor from binding platelets, has added a targeted option. In atypical hemolytic uremic syndrome, C5 complement inhibitors are the treatment of choice.
Patients with chronic hemolysis may also need monitoring for gallstones, iron overload from repeated transfusions, and, in sickle cell disease, organ complications. Knowing how normal erythrocyte function works helps make sense of why each of these complications arises. For a wider view of red cell disorders, see our anemia guide.
When to See a Doctor
Seek medical attention promptly if you notice:
- Yellowing of the skin or eyes, or dark, cola-colored urine.
- Rapidly worsening tiredness, breathlessness, or a racing heart.
- Fever while taking a complement inhibitor, which needs same-day assessment.
- Symptoms of a blood clot, such as a swollen, painful leg, chest pain, or sudden abdominal pain.
Frequently Asked Questions
Can hemolytic anemia be cured?
Some forms can. Drug-induced hemolysis often resolves once the drug is stopped, many autoimmune cases go into lasting remission, and gene therapy or transplant can offer long-term correction for some inherited forms. Others are managed as chronic conditions.
Why are steroids used for autoimmune hemolytic anemia?
Corticosteroids suppress the immune system’s production of antibodies and reduce the spleen’s clearance of antibody-coated red cells. They work well in warm AIHA but are much less effective in cold agglutinin disease.
Is iron helpful in hemolytic anemia?
Usually not. In most hemolytic anemias, iron is recycled within the body, and repeated transfusions can cause iron overload. Iron is only given if a separate iron deficiency is proven.
Do I need vaccines before starting a complement inhibitor?
Yes. Meningococcal vaccination is required before complement inhibitors, and your team may also recommend pneumococcal and Haemophilus vaccines and, in some cases, preventive antibiotics.
